- Smart Dyspnea is a tool that analyzes a person's voice in less than 20 seconds to determine if their shortness of breath requires advanced medical care, providing a fast, accurate, and affordable alternative to pulse oximeters. - It has adapted validated clinical tests to deep learning and natural language processing algorithms. Clinical validation studies are underway with results expected in June 2020. - The tool aims to monitor 1% of COPD and other respiratory disease patients and 1% of COVID-19 patients in its first year of commercialization at an annual cost of 2€ per user via APIs or as a SaaS product for health organizations. It is seeking 200,000€ in initial funding.

1. Smart Dyspnea
The early assessment that helps saving lives
Play short video

2. Smart Dyspnea
+400 Mill People with
respiratory diseases
causing 3 Mill deaths each year
+2.5 Mill people with COVID19
*www.who.int/gard/publications/The_Global_Impact_of_Respiratory_Disease.pdf
People use to feel breathless…

3. Smart Dyspnea
* Global Pulse Oximeters Market Size, Share, Industry Report, 2019-2025
Pulse oximeter is gold standard for
blood oxygen saturation
* An estimated potential market of USD 1.8 billion
$40/u.
average
…and we can know if it's serious, but
is almost impossible to read.
(and expensive)

4. Smart Dyspnea will tell you if you
need advanced health care
analyzing your own voice.
*Clinical Validation in progress. Results in June 2020
Smart Dyspnea
91% of times

5. with less than 20 seconds counting from 1 to
30 in your language.
Smart Dyspnea
FAST
ACCURATE
AFFORDABLE
Adapted valid clinical tests to Deep Learning
and Natural Language Processing algorithms
BOOSTS
ADEHERENECE

6. Smart Dyspnea
2021.032020.112020.062020.04
Smart Dyspnea Progress steps
Clinical Validation
Study Starts
01
First Working
Prototype

7. Smart Dyspnea
2021.032020.112020.062020.04
Smart Dyspnea Progress steps
Clinical Validation
Study Starts
01
First Working
Prototype
Clinical Validation
Study Ends
02
Minimum Viable
Product
Market Testing with
first clients

8. Smart Dyspnea
2021.032020.112020.062020.04
Smart Dyspnea Progress steps
Clinical Validation
Study Starts
01
First Working
Prototype
Clinical Validation
Study Ends
02
Minimum Viable
Product
Big Clinical Study
03
Algorithm
Improvements
Market Testing with
first clients
Commercialization
&
Implementation

9. Smart Dyspnea
2021.032020.112020.062020.04
Smart Dyspnea Progress steps
Clinical Validation
Study Starts
01
First Working
Prototype
Clinical Validation
Study Ends
02
Minimum Viable
Product
Big Clinical Study
03
Algorithm
Improvements
Market Testing with
first clients
Commercialization
&
Implementation
Publication of
Results
04
Technical
Upgrades
Financial
Growing

10. Chief Executive Officer (CEO) Chief Technical Officer (CTO) Business Developer (Biz Dev)
Raúl Ferrer, PhD
Digital health strategist and Clinician
Manuel Sánchez-Montañes, PhD
AI Expert
Frederic Llordach, MD
MBA and Digital Health expert
Smart Dyspnea
Smart Dyspnea Team.

11. Chief Health Officer Chief Operating Officer
Sergio Lerma, PhD
Clinical Doctor and Researcher
Smart Dyspnea
Smart Dyspnea Team.
Ignacio Gutierrez
AI and Big Data Entrepreneur

12. Business Development.
Smart Dyspnea
1% COPD patients and
other respiratory diseases
in 4 years
We are going to focus in a better control of :
1% COVID19 patients 1st year
Where?
Insurance
Companies
Private and Public
Health Centers
Patient
Associations
Pharma
Industry

13. Virtual Medical Devices - SaaS.
Smart Dyspnea
Smart Dyspnea
2€ / year
API

14. Business Development.
Smart Dyspnea
What do we need?
Up to 200.000€ 1st year for 20% actions
Premoney valoration 1 Mill €
Estimated Break-Even Point in first 10 months

15. Smart Dyspnea
The early assessment that helps saving lives